{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:19:27Z","timestamp":1792203567004,"version":"4.4.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13063-017-2024-2","type":"journal-article","created":{"date-parts":[[2017,6,15]],"date-time":"2017-06-15T12:52:11Z","timestamp":1497531131000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Non-inferiority versus superiority drug claims: the (not so) subtle distinction"],"prefix":"10.1186","volume":"18","author":[{"given":"Jitendra","family":"Ganju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dror","family":"Rom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,15]]},"reference":[{"key":"2024_CR1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1037\/1082-989X.5.4.411","volume":"5","author":"LV Jones","year":"2000","unstructured":"Jones LV, Tukey JW. A sensible formulation of the significance test. Psychol Methods. 2000;5:411\u20134.","journal-title":"Psychol Methods."},{"key":"2024_CR2","unstructured":"FDA Guidance for Industry. Non-inferiority clinical trials to establish effectiveness. 2016. http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm202140.pdf . Accessed 12 June 2017."},{"key":"2024_CR3","unstructured":"The European Agency for Evaluation of Medical Products. Points to consider on switching between superiority and non-inferiority. 2000. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003658.pdf . Accessed 12 June 2017."},{"key":"2024_CR4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/sim.2855","volume":"27","author":"TR Fleming","year":"2008","unstructured":"Fleming TR. Current issues in non-inferiority trials. Stat Med. 2008;27:317\u201332.","journal-title":"Stat Med."},{"key":"2024_CR5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/sim.1425","volume":"22","author":"RB D\u2019Agostino Sr","year":"2003","unstructured":"D\u2019Agostino Sr RB, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues\u2014the encounters of academic consultants in statistics. Stat Med. 2003;22:169\u201386.","journal-title":"Stat Med."},{"key":"2024_CR6","volume-title":"Design and analysis of non-inferiority trials","author":"MD Rothmann","year":"2012","unstructured":"Rothmann MD, Wiens BL, Chan ISF. Design and analysis of non-inferiority trials. New York: Chapman and Hall; 2012."},{"key":"2024_CR7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1745-6215-12-106","volume":"12","author":"J Shumi","year":"2011","unstructured":"Shumi J, Wittes JT. Through the looking glass: understanding non-inferiority. Trials. 2011;12:106.","journal-title":"Trials."},{"key":"2024_CR8","first-page":"150","volume":"66","author":"E Lesaffre","year":"2008","unstructured":"Lesaffre E. Superiority, equivalence and non-inferiority trials. Bull NYU Hosp Jt Dis. 2008;66:150\u20134.","journal-title":"Bull NYU Hosp Jt Dis."},{"key":"2024_CR9","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/bimj.200410089","volume":"1","author":"Y Tsong","year":"2005","unstructured":"Tsong Y, Zhang J. Testing superiority and non-inferiority hypotheses in active controlled clinical trials. Biom J. 2005;1:62\u201374.","journal-title":"Biom J."},{"key":"2024_CR10","doi-asserted-by":"crossref","first-page":"e103616","DOI":"10.1371\/journal.pone.0103616","volume":"9","author":"BP Gladstone","year":"2014","unstructured":"Gladstone BP, Vach W. Choice of non-inferiority (NI) margins does not protect against degradation of treatment effects on an average\u2014an observational study of registered and published NI trials. PLoS One. 2014;9:e103616.","journal-title":"PLoS One."},{"key":"2024_CR11","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1177\/1740774511410994","volume":"8","author":"TR Fleming","year":"2011","unstructured":"Fleming TR, et al. Some essential considerations in the design and conduct of non-inferiority trials. Clin Trials. 2011;8:432\u20139.","journal-title":"Clin Trials."},{"key":"2024_CR12","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/sim.1400","volume":"22","author":"M Rothman","year":"2003","unstructured":"Rothman M, et al. Design and analysis of non-inferiority mortality trials in oncology. Stat Med. 2003;22:239\u201364.","journal-title":"Stat Med."},{"key":"2024_CR13","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1002\/sim.4053","volume":"29","author":"S Everson-Stewart","year":"2010","unstructured":"Everson-Stewart S, Emerson SS. Bio-creep in non-inferiority clinical trials. Stat Med. 2010;29:2769\u201380.","journal-title":"Stat Med."},{"issue":"26","key":"2024_CR14","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","volume":"375","author":"SE Nissen","year":"2016","unstructured":"Nissen SE, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016;375(26):2519\u201329.","journal-title":"N Engl J Med"},{"key":"2024_CR15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/10543409508835115","volume":"5","author":"T Morikawa","year":"1995","unstructured":"Morikawa T, Yoshida M. A useful testing strategy in phase III trials. Combined test of superiority and test of equivalence. J Biopharm Stat. 1995;5:297\u2013306.","journal-title":"J Biopharm Stat"},{"key":"2024_CR16","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/sim.820","volume":"20","author":"S-J Wang","year":"2001","unstructured":"Wang S-J, et al. Group sequential test strategies for superiority and non-inferiority hypotheses in active controlled clinical trials. Stat Med. 2001;20:1903\u201312.","journal-title":"Stat Med."},{"key":"2024_CR17","unstructured":"ICH E10. Choice of control group and related issues in clinical trials. 2000. http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E10\/Step4\/E10_Guideline.pdf . Accessed 12 June 2017."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-017-2024-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T19:57:01Z","timestamp":1719259021000},"score":1,"resource":{"primary":{"URL":"http:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-017-2024-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,15]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2024"],"URL":"https:\/\/doi.org\/10.1186\/s13063-017-2024-2","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,15]]},"article-number":"278"}}